Fecal Microbiota Transplant — Identification of a New Risk

Two reports highlight the risk for transmission of multidrug-resistant organisms through fecal microbiota transplant as well as the complexity of performing the treatment safely.

The remarkable effectiveness of fecal microbiota transplantation (FMT) in treating recurrent Clostridioides difficile infections has led to a marked increase in its use for this problematic condition. In addition, FMT is now being evaluated as a potential treatment for other conditions linked to an altered intestinal microbiome, and more than 300 clinical trials on its use are listed on ClinicalTrials.gov. Still, there are safety concerns, and new reports document both the transmission of a drug-resistant pathogen through FMT as well as the complexity in trying to eliminate the risk.

DeFilipp and associates report on two patients enrolled in clinical trials who developed bacteremic infection, one fatal, due to an extended-spectrum β-lactamas…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Fecal Microbiota Transplant — Identification of a New Risk

Topics

Reviewing Author